Filter by Year
Acer Therapeutics Announces Partial Exercise of Over-allotment Option in Public Offering
NEWTON, MA – Dec. 27, 2017 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that the underwriters of its previously announced public offering of common stock have partially exercised their over-allotment option […]
Read MoreAcer Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
NEWTON, MA – Dec. 14, 2017 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced the closing of the previously announced underwritten public offering of 916,667 shares of its common stock at a […]
Read MoreAcer Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
NEWTON, MA – Dec. 14, 2017 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced the closing of the previously announced underwritten public offering of 916,667 shares of its common stock at a […]
Read MoreAcer Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
NEWTON, MA – Dec. 11, 2017 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, […]
Read MoreAcer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update Closed Merger and Concurrent $15.7M Financing Announced Positive Results from Pivotal Clinical Trial of EDSIVO™ (celiprolol) for Treatment of vEDS CAMBRIDGE, MA – Nov. 13, 2017 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization […]
Read MoreAcer Therapeutics Welcomes Two New Members to its Board of Directors
Mr. Jason Amello and Ms. Michelle Griffin Join the Board Acer Board Comprised of 7 Members Cambridge, MA – October 12, 2017 Acer Therapeutics Inc., (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced the appointments […]
Read MoreAcer Therapeutics Appoints Dr. William T. Andrews as Chief Medical Officer
Dr. Andrews’s Appointment Supports Acer’s Progression from Development to Potential Commercialization of Therapies Cambridge, MA – October 5, 2017 Acer Therapeutics Inc., (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced the appointment of William T. […]
Read MoreAcer Therapeutics Reports Positive Results From Pivotal Clinical Trial of EDSIVO™ (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome
⦁ Company intends to file NDA for EDSIVO™ in first half of 2018 – September 25, 2017 Cambridge, MA – Acer Therapeutics Inc., (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced positive results from the […]
Read MoreAcer Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
CAMBRIDGE, MA, September 22, 2017 – Acer Therapeutics Inc., (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that Chris Schelling, Chief Executive Officer and Founder, will provide a corporate overview at the Cantor Fitzgerald Global Healthcare […]
Read MoreAcer Therapeutics and Opexa Therapeutics Close Merger and Financing
Acer Therapeutics and Opexa Therapeutics Close Merger and Financing -Merger to create a pre-NDA-stage, Nasdaq-listed, pharmaceutical company focused on the development and commercialization of therapies for serious rare diseases with critical unmet medical need- -Combined company, renamed Acer Therapeutics Inc., to commence trading on Nasdaq under the symbol “ACER” on September 21- -Concurrent financing of […]
Read MoreAcer Therapeutics and Opexa Therapeutics Sign Merger Agreement
Merger to create a pre-NDA-stage, NASDAQ-listed, pharmaceutical company focused on the development and commercialization of therapies for serious rare diseases with critical unmet medical need Concurrent financing of $15.7 million from Acer investor syndicate Acer plans to file a NDA for its lead product, EDSIVO™ (celiprolol), for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in […]
Read More